A retrospective study of biopsies from stage II/III rectal cancer patients reported lower rates of pCR for tumors with KRAS mutations and higher rates of lymph node metastasis for tumors with both KRAS and TP53 mutations [11]. The gene discussed is KRAS; the disease is metastatic malignant neoplasm in the lymph nodes.